Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 15/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | S100A4 | P26447 | 1/20 | 0.34 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725950 | 0.89 | PTGES (0.47) | PTGESDRD2DRD4MEN1KMT2A | |
| SCHEMBL3094937 | 0.85 | PTGES (0.41) | PTGES | |
| SCHEMBL3101642 | 0.85 | PTGES (0.47) | PTGESMEN1KMT2APOLBHPGD | |
| SCHEMBL3106280 | 0.84 | PTGES (0.47) | PTGES | |
| SCHEMBL9939885 | 0.84 | PTGES (0.44) | PTGESDRD2DRD4 | |
| SCHEMBL3111258 | 0.84 | PTGES (0.48) | PTGESKMT2AMAPTHPGDNPSR1 | |
| SCHEMBL13190060 | 0.83 | PTGES (0.46) | PTGES | |
| SCHEMBL3094236 | 0.82 | PTGES (0.45) | PTGESMEN1KMT2AHPGD | |
| SCHEMBL3093498 | 0.82 | PTGES (0.51) | PTGESMEN1KMT2APOLBHPGD | |
| SCHEMBL3108313 | 0.81 | PTGES (0.43) | PTGESDRD2DRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| EP-2403852-B1 | 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20120196897-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196897-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885DRD2 1016/4885DRD4 716/4885 |
| US-20130303571-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885DRD2 1016/4885DRD4 716/4885 |
| US-20100256188-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885DRD2 1016/4885DRD4 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.